Just 39% of pill takers dropped to one snack a day, against 49% on shots
Novo Nordisk maintains Ozempic supply as generic rivals reach the market
Generic semaglutide uptake drove roughly 40% GLP-1 sales growth at Loblaw as weight-management drug plan spend climbs
Exposed girls showed 23% fewer follicles, but researchers stop short of blaming the drug
GLP-1s top drug plan spend reports, but the retrospective data to justify the investment doesn't exist yet, says iA's Frédéric Leblanc
Canada's Drug Agency reversed its do-not-reimburse draft, and pCPA negotiations decide what plans pay next
